Table 4.
Recent lenalidomide-free randomized trials in RRMM.
| Treatment | No. of Patients | Overall Response % | PFS—HR | PFS—Months | OS—Months | Grade ≥ 3 AE | Median (Range) of Prior Lines of Therapy | Trial Name |
|---|---|---|---|---|---|---|---|---|
| Isa-Kd vs. Kd | 302 | 87 vs. 83 | 0.53 | NR vs. 19.1 | NR | 77% vs. 67% | 2 (1−4) | IKEMA [63] |
| DKd vs. Kd | 466 | 93 vs. 86 | 0.63 | NR vs. 15.8 | NR | 82% vs. 74% | 2 (1−2) | CANDOR [62] |
| PVd vs. Vd | 559 | 82 vs. 50 | 0.61 | 11.2 vs. 7.1 | NR | NA | 2 (1−3) | OPTIMISMM [67] |
| SelVd vs. Vd | 402 | 76 vs. 62 | 0.7 | 13.9 vs. 9.5 | NR vs. 25 | NA | 1 (1−3) | BOSTON [64] |
| PanVd vs. Vd | 768 | 61 vs. 55 | 0.63 | 12 vs. 8 | 33.6 vs. 30.4 | 96% vs. 82% | 1 (1−3) | PANORAMA [65] |
Abbreviations: PFS: Progression free survival; HR: Hazard ratio; OS: Overall survival, AE: Adverse events; NR: Not reached; NA: Not available; Isa-KD: Isatuximab, carfilzomib, dexamethasone; Kd: Carfilzomib, dexamethasone; DKd: Daratumumab, carfilzomib, dexamethasone; PVd: Pomalidomide, bortezomib, dexamethasone; SelVd: Selinexor, bortezomib, dexamethasone; PanVd: Panobinostat, bortezomib, dexamethasone.